Related Experiment Videos
Trisomy 2 and 20 in two hepatoblastomas.
1Division of Human Genetics, Children's Hospital Medical Center Research Foundation, Cincinnati, Ohio 45229-2899.
Genes, Chromosomes & Cancer
|May 1, 1991
Summary
Cytogenetic analysis of pediatric hepatoblastomas reveals evolving chromosomal abnormalities, including trisomy 2 and 20, in primary tumors and metastases. These changes, particularly partial trisomy 2q and 1q, offer insights into tumor progression.
Area of Science:
- Pediatric oncology
- Cancer cytogenetics
- Tumorigenesis
Background:
- Hepatoblastoma is a rare pediatric liver cancer.
- Understanding its cytogenetic landscape is crucial for diagnosis and treatment.
- Comparative genomic hybridization (CGH) and cytogenetic analysis are key tools.
Observation:
- Two pediatric hepatoblastoma cases were analyzed.
- Samples included primary tumors, xenografts, and lung metastases.
- Chromosomal abnormalities were tracked across different stages and models.
Findings:
- Primary tumors exhibited trisomy 2 and 20, with other structural aberrations.
- Later stages (xenografts/metastases) showed structural changes in chromosome 2, leading to partial trisomy 2q.
- Partial trisomy 1q was consistently observed in advanced stages.
- Comparison with embryonal rhabdomyosarcoma highlights shared trisomy 2.
Implications:
- Cytogenetic alterations in hepatoblastoma evolve during tumor progression.
- Partial trisomy 2q and 1q may be significant in advanced disease.
- Comparative analysis aids in understanding shared mechanisms in pediatric sarcomas and carcinomas.